Genmab A/S has completed a share capital reduction by canceling 1.9 million treasury shares, reducing total share capital from DKK 64.25 million to DKK 62.35 million. The reduction was approved at the Annual General Meeting on March 19, 2026, and registered with Danish authorities on April 17, 2026. Nasdaq systems will be updated by April 21, 2026.

Orbis Investment Management Limited has disclosed a 4.99% stake in Genmab A/S as of March 27, 2026, controlling 3,205,763 shares. The announcement was made under Danish Capital Markets Act requirements. Genmab also held its Annual General Meeting on March 19, 2026, where the 2025 Annual Report was approved and discharge was given to the Board of Directors and Executive Management.

Genmab A/S issued a correction to a previous company announcement regarding managerial employee share transactions, correcting the reported share price from DKK 0.00 to DKK 1,867.50. The announcement discloses vesting and net settlement of restricted stock units granted to executives Jan van de Winkel and Anthony Pagano in February 2023.

Genmab A/S announced the vesting and net settlement of restricted stock units (RSUs) granted to executives Jan van de Winkel and Anthony Pagano on February 24, 2023, as part of deferred annual bonus achievement. The disclosure is made in accordance with EU market abuse regulations requiring transparency of insider trading activities.

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.

Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial showing epcoritamab demonstrated improvement in progression-free survival (HR: 0.74) in relapsed/refractory DLBCL patients. However, overall survival did not reach statistical significance (HR: 0.96). The company will engage regulatory authorities to discuss next steps, with additional Phase 3 trial data expected in 2026.

The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.

Genmab has successfully acquired 94.2% of Merus N.V.'s outstanding shares at $97 per share, adding petosemtamab to its portfolio and positioning itself for potential billion-dollar revenue by 2029.

Genmab will host a virtual R&D Update and ASH Data Review Meeting on December 11, 2025, presenting recent research and development insights in antibody therapeutics for cancer and serious diseases.

Genmab presented promising clinical trial results for epcoritamab, a T-cell engaging bispecific antibody, showing potential efficacy in treating Richter transformation across different treatment settings with encouraging response and survival rates.

Genmab announced positive Phase 3 trial results for EPKINLY, demonstrating significant clinical benefits in treating relapsed or refractory follicular lymphoma when combined with rituximab and lenalidomide, reducing disease progression risk by 79% and achieving a 95% overall response rate.

Genmab presented clinical trial results showing promising outcomes for epcoritamab in treating diffuse large B-cell lymphoma and follicular lymphoma, demonstrating high overall response rates and potential for fixed-duration treatment across different patient populations.